Pipeline

Macrophage-mediated diseases indications

Allocetra™ pipeline building momentum:
Strong phase 2 progress with next steps in sight

Indication:

Pre-clinical

Phase I/II

Phase II

Phase III

ENX-CL-02-002

Organ failure associated
with Sepsis

Administration:

Systemic administration

ClinicalTrials.gov ID

NCT04612413

A phase 2, multi-center, randomized, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses and regimens of Allocetra™ for the treatment of organ failure in adult sepsis patients.

View program

ENX-CL-05-001

Moderate knee
osteoarthritis

Administration:

Local knee injection

ClinicalTrials.gov ID

NCT06233474

A double blind, randomized, multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra™ compared to placebo in patients with symptomatic knee osteoarthritis.

View program

0189-22-KMC

End-stage knee
osteoarthritis

Administration:

Local knee injection

ClinicalTrials.gov ID

NCT06208241

An investigator-initiated study to assess safety and possible efficacy of Allocetra™ in end-stage knee osteoarthritis.

View program

0006-24-KMC

Basal thumb
osteoarthritis

Administration:

Local basal thumb injection

ClinicalTrials.gov ID

NCT06459063

A single center investigator-initiated trial to assess the safety and efficacy of intra-articular administration of Allocetra™ to patients with 1^ST CMC thumb joint osteoarthritis (OA).

View program

ENX-CL-06-001

Psoriatic arthritis

Administration:

Local injection to different joints

ClinicalTrials.gov ID

NCT06522035

A multi-center, open-label study to evaluate the safety and initial efficacy of Allocetra™ in patients with Psoriatic Arthritis (PsA)